Posters

Four-year outcomes of accelerated transepithelial corneal collagen cross-linking for post-LASIK ectasia

Poster Details

First Author: M.Tian CHINA

Co Author(s):    X. Zhang   W. Jian   Y. Shen   F. Xia   X. Zhou        

Abstract Details

Purpose:

To evaluate the effectiveness and safety of accelerated transepithelial corneal collagen cross linking (ATE-CXL) for post-laser-assisted in situ keratomileusis (LASIK) ectasia.

Setting:

Single-center clinical institution.

Methods:

Twelve eyes of 8 patients with post-LASIK ectasia (4 men and 4 women) undergoing ATE-CXL were enrolled in the study, with a mean spherical equivalent (SE) of -5.22±5.25 D. Corrected distance visual acuity (CDVA) and manifest refraction were assessed. Maximum keratometry (Kmax), corneal thickness (CT), and posterior elevation were measured using Pentacam preoperatively and 1, 3, 6, 12, and 48 months postoperatively. Pachymetry and epithelial thicknesses were measured using optical coherence tomography preoperatively and 3, 12, and 48 months postoperatively.

Results:

There were no complications in any of the cases during or after ATE-CXL. No significant changes were observed in CDVA and SE for up to 48 months (P > 0.05). The Kmax value was 53.18±8.45 D before the treatment and 53.11±7.96, 53.28±8.28, 51.77±6.96, 50.85±6.63, and 53.06±8.28 D 1, 3, 6, 12, and 48 months postoperatively, respectively. Throughout the whole study period Kmax, CT, and posterior elevation remained stable (P > 0.05). There was no statistically significant difference in the pachymetry results and epithelial thicknesses during 48-month follow-up (P > 0.05).

Conclusions:

The results indicate that ATE-CXL is a safe and effective treatment for post-LASIK ectatic eyes, and the corneal posterior elevation and corneal thickness tend to be stable after the treatment.

Financial Disclosure:

None